Family of one adult and five children playing game of catch on green hills

ELOCTA® was the first extended half-life recombinant Factor VIII approved in the EU

Joint protection

Introducing ELOCTA

Why ELOCTA?

Fc-fusion technology explained

Sobi’s commitment in Haemophilia

ELOCTA® was the first extended half-life recombinant Factor VIII approved in the EU

Joint protection

Introducing ELOCTA

Why ELOCTA?

Fc-fusion technology explained

Sobi’s commitment in Haemophilia